VIGL icon

Vigil Neuroscience

2.76 USD
+0.05
1.85%
At close Feb 14, 4:00 PM EST
After hours
2.77
+0.01
0.36%
1 day
1.85%
5 days
3.37%
1 month
55.06%
3 months
-13.21%
6 months
-5.48%
Year to date
55.93%
1 year
-10.97%
5 years
-78.18%
10 years
-78.18%
 

About: Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

Employees: 66

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.31% more ownership

Funds ownership: 69.62% [Q2] → 69.93% (+0.31%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

10% less capital invested

Capital invested by funds: $105M [Q2] → $94.5M (-$10.2M) [Q3]

10% less funds holding

Funds holding: 58 [Q2] → 52 (-6) [Q3]

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

33% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 18

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$17
516%
upside
Avg. target
$19.50
607%
upside
High target
$22
697%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Andrew Fein
33% 1-year accuracy
116 / 347 met price target
516%upside
$17
Buy
Reiterated
23 Jan 2025
JMP Securities
Jason Butler
43% 1-year accuracy
18 / 42 met price target
697%upside
$22
Market Outperform
Reiterated
26 Nov 2024

Financial journalist opinion

Based on 3 articles about VIGL published over the past 30 days

Neutral
GlobeNewsWire
2 weeks ago
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, at 10:30 a.m. ET.
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
Positive
Benzinga
3 weeks ago
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
On Thursday, Vigil Neuroscience Inc. VIGL released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer's disease.
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
Neutral
GlobeNewsWire
3 weeks ago
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease
- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer's disease (AD) -
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer's Disease
Neutral
GlobeNewsWire
1 month ago
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
– On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer's disease in 1Q 2025 –
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
Neutral
PRNewsWire
4 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
NEW YORK , Oct. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders.  The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
Neutral
GlobeNewsWire
5 months ago
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
WATERTOWN, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA's decision was based on a complete response submitted by the Company.
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927
Neutral
GlobeNewsWire
5 months ago
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 9:45 a.m. ET.
Vigil Neuroscience to Present at Cantor Global Healthcare Conference
Neutral
GlobeNewsWire
5 months ago
Vigil Neuroscience to Present at Upcoming September Investor Conferences
WATERTOWN, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that members of management will present at two upcoming investor conferences.
Vigil Neuroscience to Present at Upcoming September Investor Conferences
Neutral
PRNewsWire
5 months ago
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
NEW YORK , Aug. 23, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Vigil Neuroscience, Inc. (NASDAQ: VIGL) on behalf of the company's shareholders. The investigation seeks to determine whether Vigil Neuroscience's directors breached their fiduciary duties in connection with recent corporate actions.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)
Neutral
GlobeNewsWire
6 months ago
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
- Announced $40 million strategic investment from Sanofi; Extended cash runway into 2026 - - Provided update on iluzanebart clinical development strategy to pursue potential accelerated approval pathway in ALSP - - Announced interim data from VG-3927 Phase 1 trial in healthy volunteers that support continued development as potential therapy for Alzheimer's disease - WATERTOWN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2024, and provided an update on recent progress.
Vigil Neuroscience Reports Second Quarter 2024 Financial Results and Provides Business Update
Charts implemented using Lightweight Charts™